Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-09-25
DOI
10.1002/ajh.26008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies
- (2020) Naseema Gangat et al. AMERICAN JOURNAL OF HEMATOLOGY
- Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
- (2020) Ayalew Tefferi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
- (2020) Heinz Gisslinger et al. Lancet Haematology
- A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
- (2020) Bianca Rocca et al. BLOOD
- Erythrocytosis associated with cerebral hemangiomas and multiple venous anomalies
- (2020) Naseema Gangat et al. AMERICAN JOURNAL OF HEMATOLOGY
- A multicenter real‐life study on anticoagulant treatment with direct oral anticoagulants in patients with P h negative myeloproliferative neoplasms
- (2020) Alessandra Serrao et al. AMERICAN JOURNAL OF HEMATOLOGY
- Refractory Anemia with Ring Sideroblasts (RARS) and RARS with Thrombocytosis (RARS-T) - “2019 Update on Diagnosis, Risk-stratification, and Management”
- (2019) Mrinal M. Patnaik et al. AMERICAN JOURNAL OF HEMATOLOGY
- 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
- (2019) Natasha Szuber et al. MAYO CLINIC PROCEEDINGS
- Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea
- (2019) Abdulraheem Yacoub et al. BLOOD
- Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
- (2019) Emanuela Sant'Antonio et al. AMERICAN JOURNAL OF HEMATOLOGY
- Essential Thrombocythemia
- (2019) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Second cancers in MPN: Survival analysis from an international study
- (2019) Monia Marchetti et al. AMERICAN JOURNAL OF HEMATOLOGY
- Mayo CALR mutation type classification guide using alpha helix propensity
- (2018) Terra L. Lasho et al. AMERICAN JOURNAL OF HEMATOLOGY
- JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2 V617F mutated disease
- (2018) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
- (2018) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- Pregnancy oucotcome and management of 25 pregnancies in women with polycythemia vera
- (2018) Irene Bertozzi et al. AMERICAN JOURNAL OF HEMATOLOGY
- The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
- (2018) Tiziano Barbui et al. Blood Cancer Journal
- Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger
- (2018) Natasha Szuber et al. AMERICAN JOURNAL OF HEMATOLOGY
- Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide
- (2018) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features
- (2018) Anna L. Godfrey et al. JOURNAL OF CLINICAL ONCOLOGY
- MPL-mutated essential thrombocythemia: a morphologic reappraisal
- (2018) Natasha Szuber et al. Blood Cancer Journal
- Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates
- (2018) Natasha Szuber et al. Blood Cancer Journal
- Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
- (2017) S. Cerquozzi et al. Blood Cancer Journal
- Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia
- (2016) Yoseph C. Elala et al. AMERICAN JOURNAL OF HEMATOLOGY
- Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients
- (2016) Mahnur Haider et al. AMERICAN JOURNAL OF HEMATOLOGY
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Myeloproliferative neoplasms: A decade of discoveries and treatment advances
- (2015) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Ropeginterferon alfa-2b, a novel IFN -2b, induces high response rates with low toxicity in patients with polycythemia vera
- (2015) H. Gisslinger et al. BLOOD
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
- (2015) T Barbui et al. Blood Cancer Journal
- Myeloproliferative Neoplasms
- (2015) Ayalew Tefferi et al. JAMA Oncology
- Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients
- (2014) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
- (2014) Alberto Alvarez-Larrán et al. ANNALS OF HEMATOLOGY
- Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia
- (2014) G. Finazzi et al. BLOOD
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
- (2014) A. Tefferi et al. BLOOD
- Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
- (2014) G Barosi et al. LEUKEMIA
- Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia
- (2014) Bruno Cassinat et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
- (2013) H. Gisslinger et al. BLOOD
- JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
- (2013) E. T. Kuriakose et al. HAEMATOLOGICA
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
- (2013) A Tefferi et al. LEUKEMIA
- Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
- (2012) S. Pascale et al. BLOOD
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
- (2012) T. Barbui et al. BLOOD
- A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
- (2012) F. Passamonti et al. BLOOD
- GermlineJAK2Mutation in a Family with Hereditary Thrombocytosis
- (2012) Adam J. Mead et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
- (2011) A. Carobbio et al. BLOOD
- Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
- (2011) Jean-Jacques Kiladjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count
- (2010) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria
- (2010) A. Carobbio et al. BLOOD
- Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
- (2010) A. Alvarez-Larran et al. BLOOD
- Clinical utility of routineMPLexon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis
- (2010) Elaine M. Boyd et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
- (2010) A Pardanani et al. LEUKEMIA
- A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
- (2010) F Passamonti et al. LEUKEMIA
- The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)
- (2009) E. Voskaridou et al. BLOOD
- Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies
- (2009) Naseema Gangat et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia
- (2009) K. Liu et al. HAEMATOLOGICA
- Two rare MPL gene mutations in patients with essential thrombocythemia
- (2009) Haruhiko Ohashi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies
- (2009) F. PASSAMONTI et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
- (2008) A. M. Vannucchi et al. BLOOD
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
- (2008) J.-J. Kiladjian et al. BLOOD
- MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
- (2008) P. A. Beer et al. BLOOD
- Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis
- (2008) Andrew J K Östör CLINICAL RHEUMATOLOGY
- The Role of Clopidogrel and Acetylsalicylic Acid in the Prevention of Early-Phase Graft Occlusion Due to Reactive Thrombocytosis after Coronary Artery Bypass Operation
- (2008) Ilyas Kayacioglu et al. HEART SURGERY FORUM
- Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal
- (2008) A M Vannucchi et al. LEUKEMIA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started